<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5/6 nephrectomy</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2016-03-24">24 March 2016</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Oleg</forename><surname>Tsuprykov</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Institute of Nutritional Sciences</orgName>
								<orgName type="institution">University of Potsdam</orgName>
								<address>
									<settlement>Potsdam</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Center for Cardiovascular Research</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ryotaro</forename><surname>Ando</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Division of Nephrology</orgName>
								<orgName type="department" key="dep2">Department of Medicine</orgName>
								<orgName type="institution">Kurume University School of Medicine</orgName>
								<address>
									<settlement>Kurume</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department">Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications</orgName>
								<orgName type="institution">Kurume University School of Medicine</orgName>
								<address>
									<settlement>Kurume</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christoph</forename><surname>Reichetzeder</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Institute of Nutritional Sciences</orgName>
								<orgName type="institution">University of Potsdam</orgName>
								<address>
									<settlement>Potsdam</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Center for Cardiovascular Research</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Karoline</forename><surname>Von Websky</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Institute of Nutritional Sciences</orgName>
								<orgName type="institution">University of Potsdam</orgName>
								<address>
									<settlement>Potsdam</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Center for Cardiovascular Research</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Viktoriia</forename><surname>Antonenko</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Institute of Nutritional Sciences</orgName>
								<orgName type="institution">University of Potsdam</orgName>
								<address>
									<settlement>Potsdam</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Center for Cardiovascular Research</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Yuliya</forename><surname>Sharkovska</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Institute of Vegetative Anatomy</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Lyubov</forename><surname>Chaykovska</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Department of Cardiovascular Surgery</orgName>
								<orgName type="institution">University Hospital Zurich</orgName>
								<address>
									<settlement>Zurich</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jan</forename><surname>Rahnenfu ¨hrer</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Institute of Nutritional Sciences</orgName>
								<orgName type="institution">University of Potsdam</orgName>
								<address>
									<settlement>Potsdam</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Center for Cardiovascular Research</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ahmed</forename><forename type="middle">A</forename><surname>Hasan</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Institute of Nutritional Sciences</orgName>
								<orgName type="institution">University of Potsdam</orgName>
								<address>
									<settlement>Potsdam</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Harald</forename><surname>Tammen</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">PXBioVisioN GmbH</orgName>
								<address>
									<settlement>Hannover</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Markus</forename><surname>Alter</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Center for Cardiovascular Research</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="department">Department of Nephrology and Endocrinology</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Thomas</forename><surname>Klein</surname></persName>
							<affiliation key="aff8">
								<orgName type="institution">Boehringer Ingelheim Pharma GmbH &amp; Co. KG</orgName>
								<address>
									<settlement>Biberach</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Seiji</forename><surname>Ueda</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Division of Nephrology</orgName>
								<orgName type="department" key="dep2">Department of Medicine</orgName>
								<orgName type="institution">Kurume University School of Medicine</orgName>
								<address>
									<settlement>Kurume</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sho-Ichi</forename><surname>Yamagishi</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications</orgName>
								<orgName type="institution">Kurume University School of Medicine</orgName>
								<address>
									<settlement>Kurume</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Seiya</forename><surname>Okuda</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Division of Nephrology</orgName>
								<orgName type="department" key="dep2">Department of Medicine</orgName>
								<orgName type="institution">Kurume University School of Medicine</orgName>
								<address>
									<settlement>Kurume</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department">Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications</orgName>
								<orgName type="institution">Kurume University School of Medicine</orgName>
								<address>
									<settlement>Kurume</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><forename type="first">Berthold</forename><surname>Hocher</surname></persName>
							<email>hocher@uni-potsdam.de</email>
							<affiliation key="aff0">
								<orgName type="department">Institute of Nutritional Sciences</orgName>
								<orgName type="institution">University of Potsdam</orgName>
								<address>
									<settlement>Potsdam</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff9">
								<orgName type="department">Institute for Laboratory Medicine</orgName>
								<orgName type="institution">IFLB</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff10">
								<orgName type="department">Department of Basic Medicine</orgName>
								<orgName type="institution">Medical college of Hunan Normal University</orgName>
								<address>
									<settlement>Changsha</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff11">
								<orgName type="department">Institute of Nutritional Sciences</orgName>
								<orgName type="institution">University of Potsdam</orgName>
								<address>
									<postCode>14558</postCode>
									<settlement>Nuthetal, Potsdam</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5/6 nephrectomy</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2016-03-24">24 March 2016</date>
						</imprint>
					</monogr>
					<idno type="MD5">057DF02F90F0789207D411C2BE2B915E</idno>
					<note type="submission">Received 17 March 2015; revised 12 January 2016; accepted 14 January 2016;</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:15+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>albuminuria</term>
					<term>angiotensin receptor blockers</term>
					<term>chronic kidney disease</term>
					<term>DPP-4 inhibition</term>
					<term>proteinuria</term>
					<term>proteomic analysis</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Dipeptidyl peptidase (DPP)-4 inhibitors delay chronic kidney disease (CKD) progression in experimental diabetic nephropathy in a glucose-independent manner.</s><s>Here we compared the effects of the DPP-4 inhibitor linagliptin versus telmisartan in preventing CKD progression in non-diabetic rats with 5/6 nephrectomy.</s><s>Animals were allocated to 1 of 4 groups: sham operated plus placebo; 5/6 nephrectomy plus placebo; 5/6 nephrectomy plus linagliptin; and 5/6 nephrectomy plus telmisartan.</s><s>Interstitial fibrosis was significantly decreased by 48% with linagliptin but a non-significant 24% with telmisartan versus placebo.</s><s>The urine albumin-to-creatinine ratio was significantly decreased by 66% with linagliptin and 92% with telmisartan versus placebo.</s><s>Blood pressure was significantly lowered by telmisartan, but it was not affected by linagliptin.</s><s>As shown by mass spectrometry, the number of altered peptide signals for linagliptin in plasma was 552 and 320 in the kidney.</s><s>For telmisartan, there were 108 peptide changes in plasma and 363 in the kidney versus placebo.</s><s>Linagliptin up-regulated peptides derived from collagen type I, apolipoprotein C1, and heterogeneous nuclear ribonucleoproteins A2/B1, a potential downstream target of atrial natriuretic peptide, whereas telmisartan up-regulated angiotensin II.</s><s>A second study was conducted to confirm these findings in 5/6 nephrectomy wild-type and genetically deficient DPP-4 rats treated with linagliptin or placebo.</s><s>Linagliptin therapy in wild-type rats was as effective as DPP-4 genetic deficiency in terms of albuminuria reduction.</s><s>Thus, linagliptin showed comparable efficacy to telmisartan in preventing CKD progression in non-diabetic rats with 5/6 nephrectomy.</s><s>However, the underlying pathways seem to be different.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>C</head><p><s>hronic kidney disease (CKD) is a major global health problem associated with significant morbidity and mortality.</s><s>The prevalence of CKD is considered to be 8% to 16% worldwide. <ref type="bibr" target="#b0">1</ref></s><s>Although hypertension and diabetes mellitus are known to be the leading causes of CKD, a variety of other risk factors including dyslipidemia, ischemia, infection, toxins, and autoimmune and inflammatory diseases contribute to the development and progression of CKD. <ref type="bibr" target="#b1">2</ref> Reducing blood pressure (BP) using angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors is the first-line therapy for delaying CKD progression. <ref type="bibr" target="#b2">3</ref></s><s>owever, in patients who do not sufficiently respond to renin-angiotensin system inhibitors, or in whom this drug class causes major side effects, the current CKD treatment standards need to be improved.</s></p><p><s>Dipeptidyl peptidase (DPP)-4 inhibitors ("gliptins") have been approved for the treatment of type 2 diabetes mellitus since 2006.</s><s>5]<ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref> These renal effects have been demonstrated mostly in studies investigating hyperglycemic conditions.</s></p><p><s>It is well known that the antidiabetic effects of DPP-4 inhibitors are mediated via increases in levels of the incretin hormones glucagon-like peptide (GLP)-1 and glucosedependent insulinotropic polypeptide (GIP).</s><s>However, there is a broad range of other substrates for the DPP-4 enzyme including brain natriuretic peptide, substance P, peptide YY, neuropeptide Y, and stromal cell-derived factor-1 alpha (SDF-1a), which are thought to contribute to beneficial renal and cardiovascular effects; <ref type="bibr" target="#b8">9,</ref><ref type="bibr" target="#b9">10</ref> however, the underlying mechanisms have not yet been fully elucidated.</s></p><p><s>In this study, we first evaluated the glucose-independent renal effects of the DPP-4 inhibitor linagliptin in a rat 5/6 nephrectomy (5/6 Nx) model, one of the most valuable and extensively investigated experimental CKD animal models, <ref type="bibr" target="#b10">11</ref> and investigated the underlying molecular mechanisms, in comparison with those of telmisartan, one of the most commonly used angiotensin II receptor blockers.</s><s>We furthermore examined the effect of linagliptin on systolic BP (SBP) and urinary protein excretion in DPP-4-deficient mutant Fisher rats (DPP-4 -/-).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>SBP and kidney function</head><p><s>Baseline SBP levels in the first study (Core study) and in the second study (Confirmation study) are presented in Table <ref type="table" target="#tab_0">1</ref>.</s><s>SBP was not significantly affected by 5/6 Nx in any of the studies (Table <ref type="table" target="#tab_0">1</ref>).</s><s>At the end of study 1, SBP was pronouncedly lowered by telmisartan (-47.1 mm Hg, P &lt; 0.001 vs. placebo), whereas the BP-lowering effect by linagliptin was not significant (-10.8</s><s>mm Hg, NS, vs. placebo) (Table <ref type="table" target="#tab_0">1</ref>, Core study).</s><s>At the end of study 2, neither DPP-4 genetic ablation alone nor the one with linagliptin administration on its top showed any BP-lowering effect (Table <ref type="table" target="#tab_0">1</ref>, Confirmation study).</s></p><p><s>Baseline parameters of protein excretion in both studies did not differ among the treatment groups (Figure <ref type="figure" target="#fig_1">1a  and b</ref>).</s><s>At the end of study 1, urinary albumin-to-creatinine ratio was approximately 14-fold higher (P &lt; 0.001) in the placebo group versus the sham control (Figure <ref type="figure" target="#fig_1">1a</ref>), whereas it was significantly reduced following treatment with telmisartan (-92%; P &lt; 0.001) and linagliptin (-66%; P &lt; 0.001) versus placebo.</s><s>Neither linagliptin nor telmisartan lowered plasma cystatin C (Table <ref type="table" target="#tab_0">1</ref>, Core study).</s><s>At the end of study 2, urinary total protein-to-creatinine ratio was approximately 22-fold (P &lt; 0.001) higher in placebotreated 5/6 Nx wild-type rats versus sham control rats (Figure <ref type="figure" target="#fig_1">1b</ref>).</s><s>In 5/6 Nx rats, DPP-4 knockout decreased urinary total protein-to-creatinine ratio by 66% (P &lt; 0.001 vs. 5/6 Nx þ wild type) at 4 weeks of the study.</s><s>In 5/6 Nx DPP-4 -/rats, linagliptin decreased urinary total protein-tocreatinine ratio by 50% (P &lt; 0.01 vs. 5/6 Nx þ wild type) at 4 weeks of the study.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Kidney weight and morphology</head><p><s>At the end of study 1, relative kidney weight was significantly higher in placebo-treated 5/6 Nx rats versus sham control rats (Table <ref type="table" target="#tab_0">1</ref>, Core study).</s><s>Telmisartan significantly decreased kidney weight versus placebo (P &lt; 0.05), whereas linagliptin had no effect.</s><s>Compared with the sham group, 5/6 Nx numerically increased renal interstitial fibrosis by 69% (P ¼ NS) and glomerular size by 28% (P &lt; 0.01) (Figure <ref type="figure" target="#fig_0">2</ref>).</s><s>These findings were significantly attenuated by linagliptin treatment: renal interstitial fibrosis and glomerular hypertrophy (determined by glomerular size) decreased by 48% (P &lt; 0.05) and 18% (P &lt; 0.05), respectively, versus placebo (Figure <ref type="figure" target="#fig_0">2</ref>).</s><s>Telmisartan did not show any beneficial effects on kidney morphology (Figure <ref type="figure" target="#fig_0">2</ref>).</s><s>The glomerulosclerosis index was elevated in 5/6 Nx þ placebo rats (P &lt; 0.05 vs. sham) and was not restored by either telmisartan or linagliptin (Table <ref type="table" target="#tab_0">1</ref>, Core study).</s><s>Media-to-lumen ratio of intrarenal arteries and renal perivascular fibrosis showed no differences between the treatment groups (Table <ref type="table" target="#tab_0">1</ref>, Core study).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Markers of renal fibrosis and inflammation</head><p><s>In this study, 5/6 Nx resulted in an increase of fibrotic marker collagen type I and inflammatory pan-macrophage marker CD68 renal protein expression as determined by western blot (Figure <ref type="figure" target="#fig_2">3a and b</ref>).</s><s>Linagliptin, but not telmisartan, restored collagen type I renal protein expression (P &lt; 0.05 vs. placebo) (Figure <ref type="figure" target="#fig_2">3a</ref>).</s><s>In contrast, telmisartan normalized CD68 expression level (P &lt; 0.05 vs. placebo) (Figure <ref type="figure" target="#fig_2">3b</ref>), whereas linagliptin did not.</s><s>Renal protein expression of the other profibrotic markers, such as collagen type III, transforming growth factor beta 1 (TGF-b1), phospho-SMAD2-to-total SMAD2 ratio, and phospho-SMAD3-to-total SMAD2/3 ratio did not show significant differences between the study groups (Table <ref type="table" target="#tab_0">1</ref>, Core study).</s><s>Additional data on renal fibrosisassociated gene expression levels are summarized in Table <ref type="table" target="#tab_0">1</ref>, Core study.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Urinary DPP-4 activity and malondialdehyde excretion</head><p><s>Urinary DPP-4 activity, as determined by urinary DPP-4 activity-to-creatinine ratio, was decreased by linagliptin at week 18 (P &lt; 0.01 vs. placebo) (Figure <ref type="figure" target="#fig_3">4a</ref>).</s><s>Oxidative stress in the kidney, determined by urinary malondialdehydeto-creatinine ratio, was reduced by telmisartan at week 18 (P &lt; 0.01 vs. placebo), but not by linagliptin (Figure <ref type="figure" target="#fig_3">4b</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Plasma DPP-4 activity, GLP-1, GIP, SDF-1a, and glucose</head><p><s>At the end of study 1, DPP-4 activity in plasma was reduced by 72% with linagliptin (P &lt; 0.001 vs. placebo) and was not affected by telmisartan (Table <ref type="table" target="#tab_0">1</ref>, Core study).</s><s>The plasma concentration of total incretins (sum of active and inactive levels) was not significantly different between 5/6 Nx þ placebo rats and sham (P ¼ NS for GLP-1 and P ¼ NS for GIP) (Table <ref type="table" target="#tab_0">1</ref>, Core study).</s><s>Telmisartan did not affect total incretin levels, whereas linagliptin decreased total GIP levels (P &lt; 0.01 vs. placebo), but not GLP-1 levels (Table <ref type="table" target="#tab_0">1</ref>, Core study).</s><s>Linagliptin resulted in a 40.5-fold increase in active GLP-1 and a 2.2-fold increase in active GIP (P &lt; 0.001 vs. placebo for both), whereas telmisartan had no effect on active incretin plasma levels (Figure <ref type="figure" target="#fig_4">5a and b</ref>).</s><s>In addition, b a s i c r e s e a r c h</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Plasma multianalyte profiling</head><p><s>Levels of plasma osteopontin, beta-2-microglobulin, macrophage colony-stimulating factor 1, and monocyte chemoattractant protein 1 were increased in placebo-treated 5/6 Nx rats (Figure <ref type="figure" target="#fig_5">6</ref> and Table <ref type="table" target="#tab_0">1</ref>, Core study).</s><s>Linagliptin lowered plasma levels of calbindin (P &lt; 0.05).</s><s>Telmisartan decreased osteopontin (P &lt; 0.01) and macrophage colonystimulating factor 1 levels (P &lt; 0.01).</s><s>Neither drug treatment significantly reduced beta-2-microglobulin and monocyte chemoattractant protein 1 levels compared with the placebo-treated 5/6 Nx group (Figure <ref type="figure" target="#fig_5">6c</ref> and Table <ref type="table" target="#tab_0">1</ref>, Core study).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Liquid chromatography and mass spectrometry of plasma and kidney samples</head><p><s>At the end of study 1, 20 plasma (n ¼ 6 for 5/6 Nx þ placebo; n ¼ 7 for 5/6 Nx þ telmisartan; n ¼ 7 for 5/6 Nx þ linagliptin)   Subsequently, the amino acid sequences of peptides with the highest signal-to-noise ratios and absence of cysteine bridges were directly identified in plasma (Figure <ref type="figure" target="#fig_8">8a</ref>) and kidney (Figure <ref type="figure" target="#fig_8">8b</ref>) by means of tandem mass spectrometry.</s><s>Linagliptin treatment resulted in up-regulation of 4 peptides derived from collagen type I alpha 1 (3 of them in the kidney      <ref type="bibr" target="#b11">12</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCUSSION</head><p><s>In the 5/6 Nx model of CKD, telmisartan profoundly lowered SBP, whereas linagliptin showed no BP-lowering effect.</s><s>Both drugs reduced albumin excretion.</s><s>Linagliptin's action was pronounced with respect to reduction of renal interstitial fibrosis and glomerular hypertrophy.</s><s>In contrast, telmisartan's   beneficial action was mostly due to its BP-lowering effect.</s><s>The extent of the beneficial effects exerted by each drug was different.</s><s>Antiproteinuric action of linagliptin treatment was as effective as a complete DPP-4 genetic deficiency and addon linagliptin treatment in DPP-4-deficient mutant Fisher rats did not further improve the outcome.</s><s>DPP-4 inhibition by linagliptin was associated with significant increases in plasma active GLP-1, GIP, and total SDF-1a concentrations, as well as decreases in plasma and urinary DPP-4 activity.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Translation to clinical science</head><p><s>The more pronounced the proteinuria levels are, the faster CKD progresses and the higher the risk of cardiovascular complications.</s><s>Therefore, reducing proteinuria is one of the key treatment goals in CKD.</s><s>In this study, linagliptin showed an antialbuminuric effect.</s><s>Other reports, <ref type="bibr" target="#b3">4,</ref><ref type="bibr" target="#b12">13,</ref><ref type="bibr" target="#b13">14</ref> including our own, <ref type="bibr" target="#b5">6</ref> have also demonstrated the antialbuminuric action of an incretin-based therapy.</s><s>In endothelial nitric oxide synthase knockout mice with streptozotocin-induced diabetic nephropathy, linagliptin significantly reduced albumin excretion to a greater extent than telmisartan. <ref type="bibr" target="#b5">6</ref></s><s>This is consistent with findings from a pooled post hoc analysis of 4 studies in 217 patients with type 2 diabetes mellitus and renal dysfunction treated with linagliptin in addition to stable doses of renin-angiotensin system inhibitors. <ref type="bibr" target="#b13">14</ref></s><s>In another study of 36 patients with type 2 diabetes mellitus, sitagliptin significantly lowered urinary albumin-to-creatinine ratio. <ref type="bibr" target="#b12">13</ref></s><s>A reduction in albumin excretion alone may not only be a sign of improvement, but it may also be causally linked to a reduction in disease progression. <ref type="bibr" target="#b14">15</ref></s><s>Min et al. <ref type="bibr" target="#b15">16</ref> reported that in a mouse model of renal fibrosis, induced by unilateral ureteral obstruction, the DPP-4 inhibitor LC15-0444 lowered albuminuria and renal fibrosis.</s></p><p><s>8]<ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref><ref type="bibr" target="#b20">[21]</ref><ref type="bibr" target="#b21">[22]</ref><ref type="bibr" target="#b22">[23]</ref> If drugs can influence these surrogate outcomes, the likelihood that hard clinical outcomes such as a reduction in all-cause and cardiovascular mortality will be affected is high.</s><s>Therefore, the finding that linagliptin reduces kidney fibrosis and proteinuria is important from a translational perspective.</s><s>Plasma glucose levels were not affected by linagliptin (Table <ref type="table" target="#tab_0">1</ref>, Core study), indicating that the beneficial effects observed with linagliptin are glucose-independent.</s><s>In addition, the beneficial effects of linagliptin were similar regardless of the rats' genetic background (different strains, both wild type and DPP-4 -/-), suggesting that our findings are generally applicable and therefore may be translated into clinical science.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Effects of telmisartan on CKD progression</head><p><s>As expected, treatment with telmisartan resulted in potent reductions in SBP and albuminuria.</s><s>In addition, telmisartan restored plasma levels of kidney injury marker osteopontin (Figure <ref type="figure" target="#fig_5">6a</ref>).</s><s>Telmisartan exerted potent anti-inflammatory/ immunomodulatory effects as shown by decreases in renal pan-macrophage marker CD68 protein expression (Figure <ref type="figure" target="#fig_2">3b</ref>) and lowering plasma levels of macrophage colony-stimulating factor 1 (Figure <ref type="figure" target="#fig_5">6d</ref>).</s><s>In contrast, linagliptin showed no anti-inflammatory/immunomodulatory effects.</s><s>Telmisartan significantly lowered urinary malondialdehyde excretion most likely due to its antihypertensive effect.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Potential mechanism of linagliptin to reduce CKD progression</head><p><s>In the current study, we adopted a 2-pronged approach to assess potential molecular mechanisms explaining effects of DPP-4 inhibition on kidney morphology and function in 5/6 Nx rats.</s><s>We used a candidate-pathway approach and a nonhypothesis-driven peptidomics approach to explore in depth the underlying mechanisms of DPP-4 inhibition.</s><s>The candidate approach revealed that plasma levels of DPP-4 substrates such as active GLP-1, active GIP, and total SDF-1 were elevated by linagliptin in our CKD model.</s></p><p><s>We likewise tested candidate pathways such as TGF-b/ SMAD2/3 signaling.</s><s>Other groups demonstrated that DPP-4 inhibition causes a suppression of TGF-b/SMAD2/3 signaling mainly in animal models of diabetic CKD <ref type="bibr" target="#b3">4,</ref><ref type="bibr" target="#b23">24,</ref><ref type="bibr" target="#b24">25</ref> and kidney cell lines exposed to high glucose concentrations. <ref type="bibr" target="#b26">26,</ref><ref type="bibr" target="#b27">27</ref></s><s>However, in our nondiabetic CKD model, we found no evidence supporting a potential modulation of the TGF-b/SMAD2/3 pathway by linagliptin (Table <ref type="table" target="#tab_0">1</ref>, Core study).</s><s>Concerning the finding of increased plasma GLP-1, we have the opinion that the GLP-1 pathway does not contribute to a major extent to the renoprotective effects of linagliptin, because preliminary data from an ongoing study are showing that 5/6 Nx GLP-1 receptor knockout (GLP-1r -/-) mice develop interstitial fibrosis and decreased glomerular filtration rate; however, linagliptin treatment still improved kidney morphology and function (unpublished data by B. Hocher et al.).</s><s>These data strongly suggest that the GLP-1r pathway seems not to be involved in the renoprotective effects of linagliptin in our model.</s><s>In a nondiabetic rat Thy-1 glomerulonephritis model Higashijima et al. <ref type="bibr" target="#b28">28</ref> showed that both alogliptin and anagliptin reduced the number of CD68-positive inflammatory macrophages in the kidney directly via GLP-1-dependent signaling.</s><s>Because the GLP-1r pathway seems to be less important in the pathogenesis of CKD after 5/6 Nx, we did not see effects on GLP-1r-mediated kidney inflammation as it was reported by Higashijima et al. <ref type="bibr" target="#b28">28</ref> in the Thy-1 glomerulonephritis model.</s><s>Taken together, anti-inflammatory effects of DPP-4 inhibition seem to be more important in CKD models with a pronounced kidney inflammation.</s><s>The impact of the increased plasma concentrations of the DPP-4 substrates GIP and SDF-1a on the progression of kidney disease after linagliptin treatment is unknown and needs to be addressed in further studies.</s></p><p><s>The mass spectrometric analysis revealed an increased abundance of collagen type I alpha 1 fragments with N-terminal proline in the position 2-a preferable cleavage motif for DPP-4. <ref type="bibr" target="#b30">29</ref></s><s>Together with our findings of a decreased collagen I expression in the kidney, this might indicate an influence of linagliptin on collagen I homeostasis.</s><s>However, an alternative and more likely explanation of increased collagen fragments in plasma and kidney samples after linagliptin treatment is related to the fact that matrix-metalloproteases-digested collagen b a s i c r e s e a r c h O Tsuprykov et al.: Linagliptin prevents CKD progression fragments are substrates of DPP-4 and consequently increase after DPP-4 inhibition. <ref type="bibr" target="#b31">30</ref></s><s>po-C1 is an important biomolecule, participating in lipid metabolism, acting via inhibition of plasma cholesteryl ester transfer protein, an enzyme promoting the transfer of cholesterol esters and triglycerides between plasma and lipoproteins. <ref type="bibr" target="#b32">31</ref></s><s>DPP-4 is able to cleave N-terminal dipeptide containing proline in position 2 from a full-length Apo-C1 molecule, turning it into a truncated form. <ref type="bibr" target="#b33">32</ref></s><s>Our data of an increased concentration of a nontruncated Apo-C1 in the plasma after linagliptin treatment are in agreement with a recent study by Skinner et al. <ref type="bibr" target="#b34">33</ref> using sitagliptin-another DPP-4 inhibitor.</s><s>In contrast to their study, in plasma we found a &gt;95% conversion rate in placebo and an approximately 50% conversion rate after linagliptin treatment (data not shown).</s><s>Although the exact biological role of Apo-C1 truncation is not clear yet, it is hypothesized that Apo-C1 regulates protein-protein interaction with receptors involved in lipid metabolism. <ref type="bibr" target="#b33">32</ref></s><s>The levels of proatherogenic lowdensity lipoproteins were reported to be elevated as a result of any disturbances of Apo-C1 plasma concentrations (both increase and decrease). <ref type="bibr" target="#b35">34</ref></s><s>However, in our study, we mainly saw effects on kidney fibrosis.</s><s>The link between Apo-C1 and kidney fibrosis needs to be established in future studies.</s><s>Moreover, it needs to be demonstrated that a prolongation of the half-life of full-length plasma Apo-C1 might be an additional beneficial effect of DPP-4 inhibition.</s></p><p><s>We likewise found an up-regulation of HNRNPA2B1 fragment in the kidney of linagliptin-treated 5/6 Nx rats.</s><s>The representatives of type A and B HNRNPs have a high degree of amino acid sequence similarity. <ref type="bibr" target="#b36">35</ref></s><s>HNRNPA1 phosphorylation plays a major role in the downstream nuclear signaling of atrial natriuretic peptide through cyclic guanosine monophosphate and cyclic guanosine monophosphate-dependent protein kinase. <ref type="bibr" target="#b37">36</ref></s><s>In the kidney, a disturbance of atrial natriuretic peptide-mediated cyclic guanosine monophosphate synthesis is known to be a trigger of fibrosis. <ref type="bibr" target="#b37">36</ref></s><s>hus, an activation of the atrial natriuretic peptidedependent guanylate cyclase pathway may contribute to the antifibrotic properties of linagliptin. <ref type="bibr" target="#b38">37,</ref><ref type="bibr" target="#b39">38</ref></s><s>ased on our current data, which is derived from a candidate-pathway approach in combination with an open approach, and our current understanding of the mode of action of DPP-4 inhibitors, <ref type="bibr" target="#b9">10</ref> we conclude that the pharmacological effects of linagliptin cannot be explained by interacting with a single pathway.</s><s>In contrast, our hypothesis is that the beneficial effects of linagliptin are attributed to the simultaneous interference with multiple pathways.</s><s>This hypothesis is supported by our findings of the peptidomics analysis in plasma (Figure <ref type="figure" target="#fig_7">7a</ref>).</s></p><p><s>In the 5/6 Nx model, linagliptin reduced albuminuria as effectively as genetic DPP-4 deficiency and a combination of both did not further reduce albuminuria.</s><s>This suggests that the antiproteinuric effects of linagliptin are only due to the inhibition of DPP-4 activity and not due to potential pleiotropic effects of linagliptin.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Limitations</head><p><s>Although we confirmed that linagliptin treatment increased plasma active GLP-1 and GIP, as well as total SDF-1a levels, we did not evaluate other substrates of DPP-4 such as brain natriuretic peptide, substance P, peptide YY, neuropeptide Y, meprin A subunit b, and high-mobility group protein B, <ref type="bibr" target="#b9">10,</ref><ref type="bibr" target="#b40">39</ref> any of which may be responsible for the observed beneficial actions.</s><s>Additional studies using receptor knockout models for these potential DPP-4 substrates will be needed to elucidate further the mechanisms responsible for the renal effects of linagliptin.</s><s>A further limitation is the prevention style of the study, which does not mimic clinical conditions.</s><s>Furthermore, only peptides with the highest signal-to-noise ratios and absence of cysteine bridges were sequenced after being detected by liquid chromatography and mass spectrometry, thus we cannot exclude that peptides with a lower signal-to-noise ratio might have played an important role as well.</s><s>In addition, we found 26 peptides in plasma and 65 peptides in kidney (Figure <ref type="figure" target="#fig_7">7a and b</ref>), which were similarly regulated by telmisartan and linagliptin, indicating potentially overlapping renoprotective pathways of both drugs.</s><s>However, based on our strategy to start first sequencing peptides with the highest signal-to-noise ratio and the absence of cysteine bridges, these peptides were not identified yet.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusion</head><p><s>In conclusion, this study provides evidence that linagliptin delays renal disease progression in a nondiabetic, nonglucose-dependent rodent CKD model.</s><s>DPP-4 inhibition with linagliptin-and potentially other DPP-4 inhibitors also -may therefore be a novel approach for the treatment of CKD in general.</s><s>Clinical proof-of-concept studies are needed to evaluate the safety and efficacy of linagliptin in patients with nondiabetic CKD.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>MATERIALS AND METHODS Animals</head><p><s>Two independent studies were performed.</s><s>The Core study (study 1) was carried out in 50 male Wistar rats purchased from Charles River Laboratories International, Inc. (Wilmington, MA) at the age of 8 weeks.</s><s>The experiment was approved by the Committee on the Ethics of Animal Experiments (Landesamt fuer Gesundheit und Soziales), Berlin, Germany.</s><s>The second "confirmation" study (study 2) was conducted in 45 male Sprague-Dawley and F344/DuCrlCrlj (F344) genetically DPP-4-deficient rats purchased from Charles River Laboratories (Yokohama, Japan) at the age of 8 weeks.</s><s>All experimental procedures were carried out in accordance with the National Research Council of the National Academies Guide for Care and Use of Laboratory Animals and approved by the ethics committee of Kurume University, Japan.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study design</head><p><s>One week after purchase, animals in study 1 were randomly assigned to 1 of 4 groups: sham operation þ placebo (n ¼ 6); 5/6 Nx þ placebo (n ¼ 15); 5/6 Nx þ linagliptin (n ¼ 14); 5/6 Nx þ telmisartan (n ¼ 15).</s><s>The 5/6 Nx operation was performed as follows: uninephrectomy at week 1, followed at week 3 by amputation of the poles of the remaining kidney (Figure <ref type="figure" target="#fig_10">9</ref>).</s><s>Sham operations were performed at the same time points.</s><s>The duration of study 1 was 18 weeks.</s><s>During the study, SBP was measured by the tail-cuff method at weeks 0 (baseline), 7, 12, and 17.</s><s>The animals were placed in metabolic cages to obtain 24-hour urine samples at weeks 0 (baseline), 8, 13, and 18.</s><s>The rats were sacrificed at week 18 and blood samples were taken and organs harvested.</s></p><p><s>In study 2, wild-type and DPP-4 -/rats were subjected to either the sham (wild-type rats only) or 5/6 Nx operation.</s><s>The 5/6 Nx operation was performed as follows: at 8 weeks of age, the poles of right kidney were amputated (week À1), followed 1 week later by uninephrectomy (week 0, baseline) (Figure <ref type="figure" target="#fig_11">10</ref>).</s><s>Sham operations were performed at the same time points.</s><s>DPP-4 -/þ 5/6 Nx rats were subdivided into placebo and linagliptin-treatment groups.</s><s>The rats were given oral linagliptin using a stainless steel tube for 4 weeks (9 to 13 weeks of age).</s><s>Thus, the study groups were as follows: wildtype rats þ sham þ placebo (n ¼ 10); wild-type rats þ 5/6 Nx þ placebo (n ¼ 19); DPP-4 -/þ 5/6 Nx þ placebo (n ¼ 8); DPP-4 -/þ 5/6 Nx þ linagliptin (n ¼ 8).</s><s>The duration of study 2 was 4 weeks.</s><s>Final body weight, SBP, and urinary total protein were analyzed.</s><s>SBP was measured using the tail-cuff method at weeks 0 (baseline) and 4 (Figure <ref type="figure" target="#fig_11">10</ref>).</s><s>The animals were placed in metabolic cages to obtain 24-hour urine samples at weeks -1, 2, and 4. Animals were sacrificed after 4 weeks of treatment.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Drug treatments</head><p><s>Telmisartan and linagliptin were provided by Boehringer Ingelheim Pharma (Biberach an der Riss, Germany).</s><s>In study 1, linagliptin (83 mg/kg in chow) and telmisartan (5 mg/kg/day in drinking water) were administered from day 4 after the first surgery until sacrifice.</s><s>The dose of linagliptin corresponds to a dose of approximately 3 mg/kg/day; this dose has been used in previous studies. <ref type="bibr" target="#b41">40,</ref><ref type="bibr" target="#b42">41</ref></s><s>n study 2, the dose of linagliptin (administered via oral gavage daily) corresponds to a dose of approximately 3 mg/kg/day.</s><s>Control animals received vehicle only.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Renal morphometry</head><p><s>Renal morphology parameters were measured as described previously. <ref type="bibr" target="#b43">42,</ref><ref type="bibr" target="#b44">43</ref></s><s>Briefly, interstitial fibrosis was evaluated after sirius red staining using computer-aided histomorphometry devices.</s><s>Glomerular size was assessed by measuring $50 glomeruli in each longitudinal sirius red-stained kidney section using ImageJ software (National Institutes of Health, Bethesda, MD). <ref type="bibr" target="#b45">44</ref></s><s>Glomerulosclerosis was   quantified as percentage of periodic acid-Schiff-positive area within the glomerulus using a subjective semiquantitative score system (grades I-IV) by 2 investigators who were blinded to the study groups.</s><s>Media/lumen ratio was measured using ImageJ based on analysis of photomicrographs of intrarenal arteries after Elastica van Gieson staining.</s><s>Perivascular fibrosis was judged after sirius red staining using a semiquantitative score by 2 blinded independent investigators.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Protein expression analysis</head><p><s>Kidney tissue was lysed in urea/thiourea buffer (2 M thiourea, 7 M urea, 2% sodium dodecyl sulfate, 1% dithiothreitol).</s><s>All subsequent steps were performed as previously described. <ref type="bibr" target="#b46">45</ref></s><s>Details of the primary antibodies used are presented in Table <ref type="table" target="#tab_2">2</ref>. Final results were calculated as a ratio between the protein of interest and actin expression.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Real-time polymerase chain reaction-quantitation of gene expression</head><p><s>Total RNA was extracted from 50 mg of snap-frozen tissue by homogenization in peqGOLD TriFast reagent (Peqlab, Erlangen, Germany).</s><s>Residual genomic DNA was removed with TURBO DNase (Life Technologies Co., Carlsbad, CA).</s><s>RNA concentration and purity were assayed by spectrophotometry.</s><s>First-strand cDNAsynthesis was performed with random hexamer primer and 1 mg of RNA using a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Life Technologies).</s></p><p><s>Sequences from the Ensembl database and Primer3 software (available online) were used to create specific intron-spanning primers for the target genes. <ref type="bibr" target="#b47">46,</ref><ref type="bibr" target="#b48">47</ref></s><s>Primer sequences are displayed in Table <ref type="table" target="#tab_3">3</ref>. Synthesized primers were obtained from Sigma-Aldrich (St Louis, MO) or Biolegio (Nijmegen, the Netherlands).</s></p><p><s>The SensiFAST SYBR Lo-ROX kit (Bioline, London, UK) was used for real-time polymerase chain reaction amplification with 10 ng of cDNA as template and 5-to 10 pmol of each primer.</s><s>Polymerase chain reaction was performed on an Mx3000P thermal cycler (Stratagene, La Jolla, CA); all samples were analyzed in triplicate.</s><s>The amplification efficiency of every reaction was checked by linear regression method. <ref type="bibr" target="#b49">48</ref></s><s>Expression of the gene of interest was divided by the housekeeping gene (GAPDH) and expressed as fold change compared with that of the sham group.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Plasma and urine analyses</head><p><s>Urinary creatinine and albumin levels were quantitatively determined by commercially available detection kits (Immundiagnostik, Bensheim, Germany).</s><s>Plasma samples were taken at study end and analyzed for biomarker patterns by Rat KidneyMAP (version 1.0) and Rodent MAP (version 3.0) multianalyte profiling platform (Myriad RBM, Austin, TX).</s><s>DPP-4 activity was measured as reported previously. <ref type="bibr" target="#b50">49</ref></s><s>At study end, total GLP-1 and active GLP-1 (detecting 7-36 amide and 7-37) concentrations were determined by an enzyme-linked immunosorbent assay (total GLP-1: cat.</s><s>no.</s><s>K150JVC-1; active GLP-1: cat.</s><s>no.</s><s>K150JWC-1; Meso Scale Discovery, Gaithersburg, MD).</s><s>For active GIP analysis, the rat enzymelinked immunosorbent assay (cat.</s><s>no.</s><s>27202; Immuno-Biological Laboratories IBL, Minneapolis, MN) was used; for total GIP, the rat/mouse enzyme-linked immunosorbent assay (cat.</s><s>no.</s><s>EZRMGIP-55K; Millipore, Darmstadt, Germany) was used.</s><s>Malondialdehyde was detected in urine using the MDA HPLC kit (cat.</s><s>no.</s><s>KC1900; Immundiagnostik, Bensheim, Germany).</s><s>Final plasma glucose levels were determined using a clinical glucose assay reagent (Infinity Glucose Reagent; cat.</s><s>no.</s><s>TR15421; Thermo Fisher Scientific, Waltham, MA).</s><s>In study 2, urinary total protein levels were measured with a pyrogallol red-molybdate complex using Micro TP-AR2 kit (Wako Pure Chemical Industries, Osaka, Japan) and urinary creatinine concentration was measured by a colorimetric method using a Determiner-L Cre kit (Kyowa Medex Co., Ltd, Tokyo, Japan).</s><s>Liquid chromatography and mass spectrometry of plasma and kidney samples Proteins were removed by centrifugal ultrafiltration and mass spectrometric data were acquired as described previously. <ref type="bibr" target="#b31">30,</ref><ref type="bibr" target="#b51">50</ref></s><s>Briefly, after protein depletion a 0.300 ml equivalent of plasma or 7.5 mg equivalent of kidney tissue by reversed phase liquid chromatography.</s><s>After separation, each fraction was subjected to matrix-assisted laser desorption ionization time of flight mass spectrometry in linear mode.</s><s>After mass spectrometry-data acquisition, spectra were analyzed, including peak recognition and visualization using the software package Spectromania developed in-house and R 51 including the MALDIquant 52 package.</s><s>Peptide identification was achieved by matrix-assisted laser desorption ionization time of flight mass spectrometry/mass spectrometry.</s><s>Tandem mass spectrometry spectra were subsequently noise filtered and peak deisotoped and saved in Mascot (Matrix Science, London, UK) generic file format and submitted to the Mascot search engine.</s><s>Cascading searches including several post-translational modifications in UNIPROT (version 2015_09, www.uniprot.org)</s><s>were performed.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p><s>All data are expressed as means AE SEM.</s><s>Statistical analyses were performed using GraphPad Prism (version 5; GraphPad Software, San Diego, CA).</s><s>For the statistical analysis of body weight, SBP, urinary albumin-to-creatinine ratio, urinary total protein-tocreatinine ratio, a 2-way analysis of variance with Bonferroni post hoc test was used.</s><s>In all other cases, 1-way analysis of variance was used followed either by Dunn test when the data were not normally distributed or by Dunnett test when the data were normally distributed.</s><s>In all cases, differences were considered statistically significant if P &lt; 0.05.</s><s>To find relevant signals within the mass spectrometric data, statistical analysis including 2-sample t-test (Welch), Pearson product moment correlation coefficient, receiveroperating characteristics, <ref type="bibr" target="#b54">53</ref> and determination of the signal-tonoise ratio for each signal were carried out.</s><s>The thresholds for significant differences were set for plasma at P &lt; 0.01, r &gt; 0.6, the area under the receiver-operating characteristics curve &gt; 0.9 and P &lt; 0.01, r &gt; 0.7, area under the receiver-operating characteristics curve &gt; 0.95 for kidney tissue.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCLOSURE</head><p><s>TK is a research employee of Boehringer Ingelheim Pharma.</s><s>BH received a research grant from Boehringer Ingelheim Pharma for this project.</s><s>All the other authors declared no competing interests.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>aPFigure 2 |</head><label>2</label><figDesc><div><p><s>Figure 2 | Kidney morphology.</s><s>(a) Renal interstitial fibrosis, (b) typical photomicrographs of the kidneys stained with sirius red for interstitial fibrosis, (c) glomerular size, and (d) typical photomicrographs of the kidneys stained with sirius red for glomerular hypertrophy.</s><s>Values are given as mean AE SEM.</s><s>Bar ¼ 100 mm.</s><s>** P &lt; 0.01 versus sham þ placebo; # P &lt; 0.05 versus 5/6 Nx þ placebo.</s><s>NS, not significant; Nx, nephrectomy.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 1 |</head><label>1</label><figDesc><div><p><s>Figure 1 | UACR in study 1 and UPCR in study 2. (a) Urine albumin-to-creatinine ratio (UACR) in the core study (study 1) and (b) urine total protein-to-creatinine ratio (UPCR) in the confirmation study (study 2).</s><s>Values are given as mean AE SEM.</s><s>*** P &lt; 0.001 versus sham þ placebo; # P &lt; 0.05; ## P &lt; 0.01; ### P &lt; 0.001 versus 5/6 Nx þ placebo.</s><s>DPP-4, dipeptidyl peptidase-4; Nx, nephrectomy.</s></p></div></figDesc><graphic coords="4,105.11,67.52,383.75,190.49" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 3 |</head><label>3</label><figDesc><div><p><s>Figure 3 | Collagen type I and CD68 renal protein expression.</s><s>Renal relative protein expression of (a) collagen type I and (b) cluster of differentiation 68 (CD68).</s><s>Values are given as mean AE SEM.</s><s>* P &lt; 0.05 versus sham þ placebo; # P &lt; 0.05 versus 5/6 Nx þ placebo.</s><s>NS, not significant; Nx, nephrectomy.</s></p></div></figDesc><graphic coords="5,117.64,67.52,358.79,234.43" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 4 |</head><label>4</label><figDesc><div><p><s>Figure 4 | Urinary DPP-4 activity and MDA urinary excretion.</s><s>(a) Urinary dipeptidyl peptidase-4 (DPP-4) activity-to-creatinine ratio and (b) urinary malondialdehyde (MDA)-to-creatinine ratio.</s><s>To control for variations in urinary flow rate, DPP-4 activity and MDA urinary excretion were normalized to creatinine.</s><s>Values are given as mean AE SEM.</s><s>## P &lt; 0.01 versus 5/6 Nx þ placebo.</s><s>NS, not significant; Nx, nephrectomy.</s></p></div></figDesc><graphic coords="5,117.64,504.62,358.79,194.06" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Figure 5 |</head><label>5</label><figDesc><div><p><s>Figure 5 | Plasma concentration of active incretins.</s><s>(a) Plasma concentration of active glucagon-like peptide 1 (GLP-1) and (b) active glucosedependent insulinotropic polypeptide (GIP).</s><s>Values are given as mean AE SEM.</s><s>### P &lt; 0.001 versus 5/6 Nx þ placebo.</s><s>Nx, nephrectomy.</s></p></div></figDesc><graphic coords="6,117.64,67.52,358.79,195.25" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>Figure 6 |</head><label>6</label><figDesc><div><p><s>Figure 6 | Plasma parameters.</s><s>Plasma concentration of (a) osteopontin, (b) calbindin, (c) beta-2 microglobulin (b2M), and (d) macrophage colony-stimulating factor 1 (M-CSF-1).</s><s>Values are given as mean AE SEM.</s><s>** P &lt; 0.01; *** P &lt; 0.001 versus sham þ placebo; # P &lt; 0.05; ## P &lt; 0.01 versus 5/6 Nx þ placebo.</s><s>NS, not significant; Nx, nephrectomy.</s></p></div></figDesc><graphic coords="6,117.64,297.70,358.79,400.99" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_6"><head></head><label></label><figDesc><div><p><s>b a s i c r e s e a r c h O Tsuprykov et al.: Linagliptin prevents CKD progression and all 4 in plasma), 3 peptides derived from apolipoprotein C1 (Apo-C1) (in plasma only), and 2 peptides derived from heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) (in kidney only).</s><s>All aforementioned peptides contain an N-terminal proline at position 2, representing a part of the DPP-4 consensus cleavage motif, thus confirming validity of the DPP-4 inhibition.</s><s>Telmisartan treatment led to an up-regulation of angiotensin II in plasma, indicating the reliability of the results, because an elevation of angiotensin II is a known effect of angiotensin II receptor blockers therapy.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_7"><head>Figure 7 |</head><label>7</label><figDesc><div><p><s>Figure 7 | Results of univariate analyses of LC-MS data.</s><s>The circles represent the total number of statistically significant different signals as well as up-and down-regulated signals in 5/6 Nx þ telmisartan (TEL) and 5/6 Nx þ linagliptin (LIN) groups in comparison to 5/6 Nx þ placebo in (a) plasma and (b) kidney according to the results of univariate analysis of liquid chromatography and mass spectrometry (LC-MS) data.</s><s>Arrows indicate the number of overlapping signals.</s><s>Statistical thresholds: P &lt; 0.01, area under the receiver-operating characteristics curve &gt; 0.9, r &gt; 0.6 (for plasma); P &lt; 0.01, area under the receiver-operating characteristics curve &gt; 0.95, r &gt; 0.7 (for kidney).</s><s>Nx, nephrectomy.</s></p></div></figDesc><graphic coords="7,117.30,67.52,359.47,251.26" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_8"><head>Figure 8 |</head><label>8</label><figDesc><div><p><s>Figure 8 | Identified peptides sorted by their mean signal-to-noise ratios.</s><s>The bar plots depict the signal-to-noise ratios (SNRs) for identified peptides in (a) plasma and (b) kidney.</s><s>Values are given as mean AE SEM.</s><s>HNRNPA2B1, heterogeneous nuclear ribonucleoproteins A2/B1; Nx, nephrectomy.</s></p></div></figDesc><graphic coords="7,117.64,539.21,358.79,159.53" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_9"><head>O</head><label></label><figDesc><div><p><s>Tsuprykov et al.: Linagliptin prevents CKD progression b a s i c r e s e a r c h Kidney International (2016) 89, 1049-1061</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_10"><head>Figure 9 |</head><label>9</label><figDesc><div><p><s>Figure 9 | Time course of the Core study (study 1).</s><s>The experiment was started when the rats were 8 weeks old.</s><s>MC, metabolic cages (to obtain 24-hour urine samples); OP1, uninephrectomy operation on the left side; OP2, amputation of the poles of right kidney; SBP, systolic blood pressure measurements; Uni-Nx, uninephrectomy.</s></p></div></figDesc><graphic coords="10,117.64,67.52,358.79,162.54" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_11"><head>Figure 10 |</head><label>10</label><figDesc><div><p><s>Figure 10 | Time course of the confirmation study (study 2).</s><s>The study started when the rats were 8 weeks old.</s><s>MC, metabolic cages (to obtain 24-hour urine samples); OP1, amputation of the poles of right kidney; OP2, uninephrectomy operation on the left side; SBP, systolic blood pressure measurements; Uni-Nx, uninephrectomy.</s></p></div></figDesc><graphic coords="10,117.64,535.30,358.79,163.39" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_12"><head></head><label></label><figDesc><div><p><s>b a s i c r e s e a r c h O Tsuprykov et al.: Linagliptin prevents CKD progression</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_13"><head>O</head><label></label><figDesc><div><p><s>Tsuprykov et al.: Linagliptin prevents CKD progression b a s i c r e s e a r c h Kidney International (2016) 89, 1049-1061</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 ,</head><label>1</label><figDesc><div><p><s>Core study).</s></p></div></figDesc><table><row><cell>O Tsuprykov et al.: Linagliptin prevents CKD progression</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 1 |</head><label>1</label><figDesc><div><p><s>SBP, renal morphology, and function, and expression levels of fibrosis-associated genes</s></p></div></figDesc><table><row><cell>Core study (study 1)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Parameter</cell><cell cols="2">Sham D placebo</cell><cell>5/6 Nx D placebo</cell><cell>5/6 Nx D telmisartan</cell><cell>5/6 Nx D linagliptin</cell></row><row><cell>Systolic blood pressure (mm Hg)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Baseline SBP</cell><cell></cell><cell>128.50 AE 2.82</cell><cell>114.60 AE 2.41</cell><cell>115.80 AE 2.05</cell><cell>118.80 AE 2.22</cell></row><row><cell>SBP at week 7</cell><cell></cell><cell>121.88 AE 3.42</cell><cell>125.62 AE 3.14</cell><cell>91.90 AE 2.96 a</cell><cell>114.00 AE 2.87 b</cell></row><row><cell>SBP at week 12</cell><cell></cell><cell>128.48 AE 4.18</cell><cell>132.42 AE 4.65</cell><cell>88.89 AE 2.34 a</cell><cell>125.29 AE 4.14</cell></row><row><cell>SBP at week 17</cell><cell></cell><cell>121.00 AE 4.51</cell><cell>134.30 AE 3.98</cell><cell>87.22 AE 3.85 a</cell><cell>123.50 AE 3.33</cell></row><row><cell>Kidney morphology</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Final body weight (g)</cell><cell></cell><cell>591.0 AE 34.1</cell><cell>588.3 AE 10.4</cell><cell>542.1 AE 19.7</cell><cell>560.3 AE 18.1</cell></row><row><cell cols="2">Relative weight of left kidney (mg/g)</cell><cell>2.85 AE 0.14</cell><cell>4.39 AE 0.29 c</cell><cell>3.47 AE 0.11 b</cell><cell>4.32 AE 0.24 c</cell></row><row><cell>GS index (score)</cell><cell></cell><cell>1.72 AE 0.05</cell><cell>2.02 AE 0.07 d</cell><cell>1.87 AE 0.06</cell><cell>1.90 AE 0.04</cell></row><row><cell>Media-to-lumen ratio</cell><cell></cell><cell>2.66 AE 0.18</cell><cell>2.62 AE 0.12</cell><cell>2.69 AE 0.18</cell><cell>2.62 AE 0.22</cell></row><row><cell>Renal perivascular fibrosis (score)</cell><cell></cell><cell>1.92 AE 0.26</cell><cell>1.88 AE 0.13</cell><cell>1.73 AE 0.17</cell><cell>1.77 AE 0.10</cell></row><row><cell>Plasma parameters</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Final plasma glucose (mmol/l)</cell><cell></cell><cell>8.08 AE 0.29</cell><cell>7.65 AE 0.26</cell><cell>8.13 AE 0.26</cell><cell>7.67 AE 0.23</cell></row><row><cell>Cystatin C (ng/ml)</cell><cell></cell><cell>695 AE 37.83</cell><cell>1528 AE 97.65 c</cell><cell>1356 AE 61.38 d</cell><cell>1443 AE 72.66 e</cell></row><row><cell>MCP-1 in plasma</cell><cell></cell><cell>423.3 AE 72.44</cell><cell>665.9 AE 42.74 e</cell><cell>533.2 AE 35.78</cell><cell>664.1 AE39.17 e</cell></row><row><cell cols="2">DPP-4 activity in plasma, arbitrary units</cell><cell>173,721 AE 6733</cell><cell>165,082 AE 6957</cell><cell>151,075 AE 6102</cell><cell>46,198 AE 1792 a,c</cell></row><row><cell>Total GLP-1 (pg/ml)</cell><cell></cell><cell>14.26 AE 5.73</cell><cell>23.13 AE 3.33</cell><cell>27.48 AE 4.08</cell><cell>24.54 AE 3.48</cell></row><row><cell>Total GIP (pg/ml)</cell><cell></cell><cell>227.3 AE 21.10</cell><cell>368.0 AE 39.01</cell><cell>312.7 AE 31.46</cell><cell>210.1 AE 39.63 f</cell></row><row><cell>Total SDF-1a (ng/ml)</cell><cell></cell><cell>221.5 AE 107.2</cell><cell>802.1 AE 388.7</cell><cell>910.3 AE 444.7</cell><cell>1301.0 AE 194.6 b,e</cell></row><row><cell cols="2">Relative protein expression in the kidney</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">Collagen type III (relative protein expression)</cell><cell>1.00 AE 0.08</cell><cell>1.33 AE 0.09</cell><cell>1.20 AE 0.09</cell><cell>1.29 AE 0.09</cell></row><row><cell cols="2">TGF-b1 (relative protein expression)</cell><cell>1.00 AE 0.10</cell><cell>1.25 AE 0.10</cell><cell>0.93 AE 0.10</cell><cell>1.04 AE 0.08</cell></row><row><cell cols="2">Phospho-SMAD2 (relative protein expression)</cell><cell>1.00 AE 0.21</cell><cell>1.21 AE 0.12</cell><cell>0.91 AE 0.11</cell><cell>0.90 AE 0.16</cell></row><row><cell cols="2">Total SMAD2 (relative protein expression)</cell><cell>1.00 AE 0.10</cell><cell>1.12 AE 0.09</cell><cell>0.92 AE 0.08</cell><cell>0.88 AE 0.06</cell></row><row><cell cols="2">Phospho-SMAD2/total SMAD2 ratio</cell><cell>1.00 AE 0.23</cell><cell>1.08 AE 0.15</cell><cell>0.89 AE 0.13</cell><cell>1.04 AE 0.16</cell></row><row><cell cols="2">Phospho-SMAD3 (relative protein expression)</cell><cell>1.00 AE 0.12</cell><cell>1.09 AE 0.21</cell><cell>1.34 AE 0.19</cell><cell>1.19 AE 0.16</cell></row><row><cell cols="2">Total SMAD2/3 (relative protein expression)</cell><cell>1.00 AE 0.11</cell><cell>1.06 AE 0.08</cell><cell>0.82 AE 0.05</cell><cell>0.95 AE 0.08</cell></row><row><cell cols="2">Phospho-SMAD3/total SMAD2/3 ratio</cell><cell>1.00 AE 0.13</cell><cell>1.17 AE 0.34</cell><cell>1.62 AE 0.25</cell><cell>1.39 AE 0.25</cell></row><row><cell cols="2">Relative gene expression in the kidney</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">Collagen type Ia1 (relative gene expression)</cell><cell>1.00 AE 0.25</cell><cell>5.23 AE 1.54 e</cell><cell>1.94 AE 0.28</cell><cell>3.27 AE 0.97 d</cell></row><row><cell cols="2">Collagen type IIIa1 (relative gene expression)</cell><cell>1.00 AE 0.35</cell><cell>4.06 AE 1.20 d</cell><cell>1.40 AE 0.22</cell><cell>2.77 AE 0.88</cell></row><row><cell>TGF-b1 (relative gene expression)</cell><cell></cell><cell>1.00 AE 0.37</cell><cell>2.01 AE 0.37 d</cell><cell>0.94 AE 0.10 b</cell><cell>1.50 AE 0.27</cell></row><row><cell>TIMP-1 (relative gene expression)</cell><cell></cell><cell>1.00 AE 0.52</cell><cell>2.38 AE 0.46 d</cell><cell>0.81 AE 0.11 b</cell><cell>1.80 AE 0.51</cell></row><row><cell cols="2">GLP-1 receptor (relative gene expression)</cell><cell>1.00 AE 0.30</cell><cell>1.27 AE 0.29</cell><cell>2.02 AE 0.80</cell><cell>1.93 AE 0.48</cell></row><row><cell>Confirmation study (study 2)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>5/6 Nx D</cell><cell>5/6 Nx D</cell></row><row><cell>Parameter</cell><cell>Sham D placebo</cell><cell cols="2">5/6 Nx D placebo</cell><cell>DPP-4 -/-D placebo</cell><cell>DPP-4 -/-D linagliptin</cell></row><row><cell>Baseline SBP (mm Hg)</cell><cell>115.8 AE 7.7</cell><cell cols="2">118.5 AE 6.6</cell><cell>121.2 AE 8.7</cell><cell>116.8 AE 6.0</cell></row><row><cell>SBP at week 4 (mm Hg)</cell><cell>108.4 AE 10.0</cell><cell cols="2">159.4 AE 30.5</cell><cell>120.6 AE 12.3</cell><cell>133.9 AE 24.3</cell></row></table><note><p><s>DPP-4, dipeptidyl peptidase-4; GIP, glucose-dependent insulinotropic polypeptide; GLP-1, glucagon-like peptide 1; GS, glomerulosclerosis; MCP-1, monocyte chemoattractant protein 1; Nx, nephrectomy; SBP, systolic blood pressure; SDF-1a, stromal cell-derived factor-1 alpha; TGF-b1, transforming growth factor beta 1; TIMP-1, tissue inhibitor of metalloproteinase 1.</s><s>Values are given as mean AESEM.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 2 |</head><label>2</label><figDesc><div><p><s>List of primary antibodies used</s></p></div></figDesc><table><row><cell>Product</cell><cell></cell><cell>Catalog</cell><cell>Host</cell><cell></cell></row><row><cell>name</cell><cell>Manufacturer</cell><cell>no.</cell><cell cols="2">species Dilution</cell></row><row><cell>Actin</cell><cell cols="2">Sigma-Aldrich (St. Louis, MO) A5060</cell><cell cols="2">Rabbit 1:50,000</cell></row><row><cell>Collagen</cell><cell>Acris Antibodies GmbH</cell><cell>R1038</cell><cell cols="2">Rabbit 1:1000</cell></row><row><cell>type I</cell><cell>(Herford, Germany)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Collagen</cell><cell>Acris Antibodies</cell><cell cols="3">13548-1-AP Rabbit 1:1000</cell></row><row><cell>type III</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>CD68 (ED-1)</cell><cell>Santa Cruz Biotechnologies</cell><cell cols="3">sc-59103 Mouse 1:1000</cell></row><row><cell></cell><cell>(Santa Cruz, CA)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Phospho-</cell><cell>Merck Millipore (Billerica,</cell><cell>04-953</cell><cell cols="2">Rabbit 1:1000</cell></row><row><cell>SMAD2</cell><cell>MA)</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="3">Total SMAD2 Santa Cruz Biotechnologies sc-6200</cell><cell>Goat</cell><cell>1:500</cell></row><row><cell>Phospho-</cell><cell>Cell Signaling (Beverly, MA)</cell><cell>C25A9</cell><cell cols="2">Rabbit 1:2000</cell></row><row><cell>SMAD3</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Total</cell><cell cols="2">Santa Cruz Biotechnologies sc-6202</cell><cell>Goat</cell><cell>1:500</cell></row><row><cell>SMAD2/3</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>TGF-b1</cell><cell>Santa Cruz Biotechnologies</cell><cell>sc-146</cell><cell>Rabbit</cell><cell>1:500</cell></row><row><cell cols="5">CD68, cluster of differentiation 68; TGF-b1, transforming growth factor beta 1.</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 3 |</head><label>3</label><figDesc><div><p><s>Real-time polymerase chain reaction primers</s></p></div></figDesc><table><row><cell>Gene</cell><cell>Primer sequence</cell><cell>Length</cell><cell>Exons</cell></row><row><cell>TGF-b1</cell><cell>þ CCAAGGAGACGGAATACAGG</cell><cell>101</cell><cell>2-4</cell></row><row><cell>ENSRNOG00000020652</cell><cell>-GTTTGGGACTGATCCCATTG</cell><cell></cell><cell></cell></row><row><cell>TIMP-1</cell><cell>þ CGGACCTGGTTATAAGGGCTA</cell><cell>104</cell><cell>2-4</cell></row><row><cell>ENSRNOG00000010208</cell><cell>-GAATCCTTTGAGCATCTTAGTCATC</cell><cell></cell><cell></cell></row><row><cell>Collagen type Ia1</cell><cell>þ TGGATTCCAGTTCGAGTATGG</cell><cell>129</cell><cell>49-50</cell></row><row><cell>ENSRNOG00000003897</cell><cell>-GCTACGCTGTTCTTGCAGTG</cell><cell></cell><cell></cell></row><row><cell>Collagen type IIIa1</cell><cell>þ CAATGTAGATGAATTGGGATGC</cell><cell>119</cell><cell>1-2</cell></row><row><cell>ENSRNOG00000003357</cell><cell>-TGTCATCACAGAGGACAGATCC</cell><cell></cell><cell></cell></row><row><cell>GLP-1 receptor</cell><cell>þ CAATCGGGGTCAACTTCCT</cell><cell>109</cell><cell>10-12</cell></row><row><cell>ENSRNOG00000001152</cell><cell>-GACTTCGCGAGTCTGCATTT</cell><cell></cell><cell></cell></row><row><cell>GAPDH</cell><cell>þ CCATCAACGACCCCTTCAT</cell><cell>150</cell><cell>3-4</cell></row><row><cell>ENSRNOG00000018630</cell><cell>-GATCTCGCTCCTGGAAGATG</cell><cell></cell><cell></cell></row></table><note><p><s>GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GLP-1, glucagon-like peptide 1; TGF-b1, transforming growth factor beta 1; TIMP-1, tissue inhibitor of metalloproteinase.</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Kidney International (2016) 89, 1049-1061</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">O Tsuprykov et al.: Linagliptin prevents CKD progression b a s i c r e s e a r c h Kidney International (2016) 89, 1049-1061</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ACKNOWLEDGMENTS</head><p><s>The authors were fully responsible for all content and editorial decisions, were involved at all stages of manuscript development, and have approved the final version.</s><s>Editorial assistance, supported financially by Boehringer Ingelheim, was provided by Paul MacCallum, PhD, of Envision Scientific Solutions during the preparation of this manuscript.</s></p></div>
			</div>

			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Chronic kidney disease: global dimension and perspectives</title>
		<author>
			<persName><forename type="first">V</forename><surname>Jha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Garcia-Garcia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Iseki</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">382</biblScope>
			<biblScope unit="page" from="260" to="272" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Chronic kidney disease: prevention and treatment of common complications</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Snively</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Gutierrez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am Fam Physician</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="page" from="1921" to="1928" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Novel drugs and intervention strategies for the treatment of chronic kidney disease</title>
		<author>
			<persName><forename type="first">Lambers</forename><surname>Heerspink</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>De Zeeuw</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Clin Pharmacol</title>
		<imprint>
			<biblScope unit="volume">76</biblScope>
			<biblScope unit="page" from="536" to="550" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Xie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">N</forename><surname>Liu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Pharmacol Exp Ther</title>
		<imprint>
			<biblScope unit="volume">340</biblScope>
			<biblScope unit="page" from="248" to="255" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes</title>
		<author>
			<persName><forename type="first">J</forename><surname>Vaghasiya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Sheth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Bhalodia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Manek</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Regul Pept</title>
		<imprint>
			<biblScope unit="volume">166</biblScope>
			<biblScope unit="page" from="48" to="54" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Alter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">M</forename><surname>Ott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Von Websky</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Kidney Blood Press Res</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="119" to="130" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Attenuation of renovascular damage in Zucker diabetic fatty rat by NWT-03, an egg protein hydrolysate with ACE-and DPP4-inhibitory activity</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Landheer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Van Gilst</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page">e46781</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat)</title>
		<author>
			<persName><forename type="first">C</forename><surname>Mega</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">T</forename><surname>De Lemos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Vala</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Exp Diabetes Res</title>
		<imprint>
			<biblScope unit="page">162092</biblScope>
			<date type="published" when="2011">2011. 2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Cardiovascular effects of antidiabetic agents: focus on blood pressure effects of incretin-based therapies</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">J</forename><surname>Brown</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Soc Hypertens</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="163" to="168" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Renal and cardiac effects of DPP4 inhibitors-from preclinical development to clinical research</title>
		<author>
			<persName><forename type="first">B</forename><surname>Hocher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Reichetzeder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Alter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Kidney Blood Press. Res</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="65" to="84" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Investigating mechanisms of chronic kidney disease in mouse models</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Eddy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>López-Guisa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Okamura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Yamaguchi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pediatr Nephrol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="1233" to="1247" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension</title>
		<author>
			<persName><forename type="first">T</forename><surname>Tsutamoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Nishiyama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Yamaji</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hypertens Res</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="118" to="122" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Sitagliptin reduces albuminuria in patients with type 2 diabetes</title>
		<author>
			<persName><forename type="first">S</forename><surname>Hattori</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Endocr J</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="69" to="73" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Groop</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Cooper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Perkovic</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="3460" to="3468" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT Study</title>
		<author>
			<persName><forename type="first">G</forename><surname>Remuzzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Macia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ruggenenti</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Soc Nephrol</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="S90" to="S97" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Dipeptidyl peptidase IV inhibitor protects against renal interstitial fibrosis in a mouse model of ureteral obstruction</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Min</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Lee</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lab Invest</title>
		<imprint>
			<biblScope unit="volume">94</biblScope>
			<biblScope unit="page" from="598" to="607" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Therapeutic strategies to slow chronic kidney disease progression</title>
		<author>
			<persName><forename type="first">E</forename><surname>Wühl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Schaefer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pediatr Nephrol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="705" to="716" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">The role of proteinuria in the progression of chronic renal failure</title>
		<author>
			<persName><forename type="first">C</forename><surname>Burton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">P</forename><surname>Harris</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Kidney Dis</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="765" to="775" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Blood pressure control, proteinuria, and the progression of renal disease: the Modification of Diet in Renal Disease Study</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Peterson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Adler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Burkart</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">123</biblScope>
			<biblScope unit="page" from="754" to="762" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Progression of renal insufficiency: role of blood pressure</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Brazy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">W</forename><surname>Stead</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Fitzwilliam</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Kidney Int</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="670" to="674" />
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Pharmacologic issues in treating hypertension in CKD</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Sica</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Adv Chronic Kidney Dis</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="42" to="47" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">How does early chronic kidney disease progress? A background paper prepared for the UK Consensus Conference on early chronic kidney disease</title>
		<author>
			<persName><forename type="first">W</forename><surname>Metcalfe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nephrol Dial Transplant</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="26" to="30" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note>suppl</note>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Treatment targets in renal fibrosis</title>
		<author>
			<persName><forename type="first">P</forename><surname>Boor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Sebeková</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ostendorf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Floege</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nephrol Dial Transplant</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="3391" to="3407" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen</title>
		<author>
			<persName><forename type="first">K</forename><surname>Kanasaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Shi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kanasaki</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diabetes</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="2120" to="2131" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<monogr>
		<title level="m" type="main">Saxagliptin reduces renal tubulointerstitial inflammation, hypertrophy and fibrosis in diabetes</title>
		<author>
			<persName><forename type="first">M</forename><surname>Gangadharan Komala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gross</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Zaky</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>e-pub ahead of print</note>
</biblStruct>

<biblStruct xml:id="b25">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">(</forename><surname>Nephrology</surname></persName>
		</author>
		<author>
			<persName><surname>Carlton</surname></persName>
		</author>
		<idno type="DOI">10.1111/nep.12618</idno>
		<ptr target="http://dx.doi.org/10.1111/nep.12618" />
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">DPP4 inhibition in human kidney proximal tubular cells-renoprotection in diabetic nephropathy?</title>
		<author>
			<persName><forename type="first">U</forename><surname>Panchapakesan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gross</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Komala</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Diabetes Metab</title>
		<imprint>
			<biblScope unit="page">1</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Linagliptin limits high glucose induced conversion of latent to active TGFß through interaction with CIM6PR and limits renal tubulointerstitial fibronectin</title>
		<author>
			<persName><forename type="first">M</forename><surname>Gangadharan Komala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gross</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Zaky</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">e0141143</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Anti-inflammatory role of DPP-4 inhibitors in a nondiabetic model of glomerular injury</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Higashijima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Tanaka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Yamaguchi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Physiol Renal Physiol</title>
		<imprint>
			<biblScope unit="volume">308</biblScope>
			<biblScope unit="page" from="F878" to="F887" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<monogr>
		<title level="m" type="main">Linagliptin prevents CKD progression</title>
		<author>
			<persName><forename type="first">O</forename><surname>Tsuprykov</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Peptidase substrates via global peptide profiling</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Tagore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">M</forename><surname>Nolte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Neveu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Chem Biol</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="23" to="25" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">In vivo profiling of DPP4 inhibitors reveals alterations in collagen metabolism and accumulation of an amyloid peptide in rat plasma</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Jost</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lamerz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Tammen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochem Pharmacol</title>
		<imprint>
			<biblScope unit="volume">77</biblScope>
			<biblScope unit="page" from="228" to="237" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Apolipoprotein CI overexpression is not a relevant strategy to block cholesteryl ester transfer protein (CETP) activity in CETP transgenic mice</title>
		<author>
			<persName><forename type="first">T</forename><surname>Gautier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Masson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Jong</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochem J</title>
		<imprint>
			<biblScope unit="volume">385</biblScope>
			<biblScope unit="page" from="189" to="195" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Top-down proteomic analysis by MALDI-TOF profiling: concentration-independent biomarkers</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">L</forename><surname>Nelsestuen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Harvey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proteomics Clin Appl</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="158" to="166" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Sitagliptin results in a decrease of truncated apolipoprotein C1</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">E</forename><surname>Skinner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Wroblewski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Kirihara</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diabetes Ther</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="395" to="401" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Human apolipoprotein C-I accounts for the ability of plasma high density lipoproteins to inhibit the cholesteryl ester transfer protein activity</title>
		<author>
			<persName><forename type="first">T</forename><surname>Gautier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Masson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>De Barros</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">275</biblScope>
			<biblScope unit="page" from="37504" to="37509" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Nuclear functions of heterogeneous nuclear ribonucleoproteins A/B</title>
		<author>
			<persName><forename type="first">Y</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Smith</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell Mol Life Sci</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="1239" to="1256" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Heterogeneous nuclear ribonucleoprotein A1 is a novel cellular target of atrial natriuretic peptide signaling in renal epithelial cells</title>
		<author>
			<persName><forename type="first">B</forename><surname>Hesabi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Danziger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">U</forename><surname>Kotlo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell Signal</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="1100" to="1108" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Natriuretic peptide/ natriuretic peptide receptor-A (NPR-A) system has inhibitory effects in renal fibrosis in mice</title>
		<author>
			<persName><forename type="first">T</forename><surname>Nishikimi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Inaba-Iemura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ishimura</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Regul Pept</title>
		<imprint>
			<biblScope unit="volume">154</biblScope>
			<biblScope unit="page" from="44" to="53" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Suppression of atrial natriuretic peptide/natriuretic peptide receptor-A-mediated signaling upregulates angiotensin-II-induced collagen synthesis in adult cardiac fibroblasts</title>
		<author>
			<persName><forename type="first">A</forename><surname>Parthasarathy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Gopi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Umadevi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Cell Biochem</title>
		<imprint>
			<biblScope unit="volume">378</biblScope>
			<biblScope unit="page" from="217" to="228" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Muskiet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Smits</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Morsink</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Diamant</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Nephrol</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="88" to="103" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Dipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistant male Zucker obese rats</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Aroor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Sowers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Bender</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Endocrinology</title>
		<imprint>
			<biblScope unit="volume">154</biblScope>
			<biblScope unit="page" from="2501" to="2513" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">DPP4 inhibition attenuates filtration barrier injury and oxidant stress in the Zucker obese rat</title>
		<author>
			<persName><forename type="first">R</forename><surname>Nistala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Habibi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Aroor</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Obesity (Silver Spring)</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="2172" to="2179" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">ETA receptor blockade induces fibrosis of the clipped kidney in two-kidney-one-clip renovascular hypertensive rats</title>
		<author>
			<persName><forename type="first">B</forename><surname>Hocher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>George</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Diekmann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Hypertens</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="1807" to="1814" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Systemic cardiovascular disease in uremic rats induced by 1,25(OH)2D3</title>
		<author>
			<persName><forename type="first">D</forename><surname>Haffner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Hocher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Müller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Hypertens</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="1067" to="1075" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">S</forename><surname>Rasband</surname></persName>
		</author>
		<author>
			<persName><surname>Imagej</surname></persName>
		</author>
		<author>
			<persName><surname>Bethesda</surname></persName>
		</author>
		<author>
			<persName><forename type="middle">S</forename><surname>Md: U</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">National Institutes of Health</title>
		<imprint>
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Endothelin-1 overexpression improves renal function in eNOS knockout mice</title>
		<author>
			<persName><forename type="first">O</forename><surname>Tsuprykov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Chaykovska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kretschmer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell Physiol Biochem</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="1474" to="1490" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">P</forename><surname>Flicek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Amode</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Barrell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nucleic Acids Res</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="D84" to="D90" />
			<date type="published" when="2012">2012. 2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Primer3-new capabilities and interfaces</title>
		<author>
			<persName><forename type="first">A</forename><surname>Untergasser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Cutcutache</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Koressaar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nucleic Acids Res</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page">e115</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data</title>
		<author>
			<persName><forename type="first">C</forename><surname>Ramakers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Ruijter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">H</forename><surname>Deprez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">F</forename><surname>Moorman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurosci Lett</title>
		<imprint>
			<biblScope unit="volume">339</biblScope>
			<biblScope unit="page" from="62" to="66" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy</title>
		<author>
			<persName><forename type="first">L</forename><surname>Chaykovska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Von Websky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Rahnenführer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">e27861</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Peptidomic analysis of human blood specimens: comparison between plasma specimens and serum by differential peptide display</title>
		<author>
			<persName><forename type="first">H</forename><surname>Tammen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Schulte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hess</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proteomics</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="3414" to="3422" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">R: A Language and Environment for Statistical Computing</title>
		<author>
			<persName><surname>R Core Team</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">R Foundation for Statistical Computing</title>
				<meeting><address><addrLine>Vienna, Austria</addrLine></address></meeting>
		<imprint>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">MALDIquant: a versatile R package for the analysis of mass spectrometry data</title>
		<author>
			<persName><forename type="first">S</forename><surname>Gibb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Strimmer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bioinformatics</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="2270" to="2271" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">pROC: an open-source package for R and Sþ to analyze and compare ROC curves</title>
		<author>
			<persName><forename type="first">X</forename><surname>Robin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Turck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hainard</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Bioinformatics</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">77</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
